HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Price, Forecast & Analysis
Europe • Euronext Brussels • EBR:HYL • BE0974363955
HYL.BR Key Statistics, Chart & Performance
The current stock price of HYL.BR is 7.76 EUR. In the past month the price increased by 11.14%. In the past year, price increased by 48.33%.
HYL.BR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HYL.BR. When comparing the yearly performance of all stocks, HYL.BR is one of the better performing stocks in the market, outperforming 93.6% of all stocks.
HYL.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR. While HYL.BR seems to be doing ok healthwise, there are quite some concerns on its profitability.
HYL.BR Financial Highlights
Over the last trailing twelve months HYL.BR reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 46.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.31% | ||
| ROE | -22.2% | ||
| Debt/Equity | 0.06 |
HYL.BR Forecast & Estimates
7 analysts have analysed HYL.BR and the average price target is 13.84 EUR. This implies a price increase of 78.32% is expected in the next year compared to the current price of 7.76.
For the next year, analysts expect an EPS growth of 38.32% and a revenue growth 77.8% for HYL.BR
HYL.BR Ownership
About HYL.BR
Company Profile
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 40 full-time employees. The company went IPO on 2020-06-29. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
Company Info
HYLORIS PHARMACEUTICALS SA
Boulevard Patience et Beaujonc
Liege LIEGE BE
Employees: 49
Phone: 3243460207
HYLORIS PHARMACEUTICALS SA / HYL.BR FAQ
What does HYL do?
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 40 full-time employees. The company went IPO on 2020-06-29. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
What is the stock price of HYLORIS PHARMACEUTICALS SA today?
The current stock price of HYL.BR is 7.76 EUR. The price decreased by -2.76% in the last trading session.
What is the dividend status of HYLORIS PHARMACEUTICALS SA?
HYL.BR does not pay a dividend.
What is the ChartMill technical and fundamental rating of HYL stock?
HYL.BR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is HYLORIS PHARMACEUTICALS SA worth?
HYLORIS PHARMACEUTICALS SA (HYL.BR) has a market capitalization of 217.28M EUR. This makes HYL.BR a Micro Cap stock.
Can you provide the upcoming earnings date for HYLORIS PHARMACEUTICALS SA?
HYLORIS PHARMACEUTICALS SA (HYL.BR) will report earnings on 2026-03-26, after the market close.